Skip to main content

Table 1 Effect of Zt/g4-Directed DM1 Delivery on Cell Cycle Changes by human breast and NSCLC Cell Linesa

From: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Cancer cell lines Changes of cell cycles after Zt/g4-DM1 treatment (%)
  G0/G1 phase S phase G2/M phase
  0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h
MCF7 50.49 51.56 47.59 42.19 23.95 23.75 25.08 26.78 25.57 24.69 27.33 31.03
DU4475 51.14 40.92 23.22 10.13 10.42 18.24 16.37 13.5 38.42 40.91 60.40 76.37
MDA-MB-231 48.38 35.40 17.56 7.23 17.52 25.21 21.90 10.05 34.24 39.50 60.63 82.62
T-47D 64.71 62.81 35.63 14.74 7.06 10.15 28.61 10.29 28.24 27.04 35.76 74.97
H1993 56.40 54.55 53.28 50.17 16.00 16.53 18.03 15.87 27.60 28.93 28.69 33.95
H2228 63.56 58.23 48.85 27.21 13.98 13.92 12.95 8.16 22.46 27.85 38.20 64.63
H358 46.60 29.22 28.13 18.69 14.63 17.81 18.23 14.65 38.78 52.97 53.65 66.67
  1. aBreast and NSCLC cell lines at 1 × 106 cells per culture dish in DMEM with 10 % FBS were treated at 37 °C for 0, 6, 12 and 24 h with 5 μg/ml of Zt/g4-DM1. After treatment, cells were labeled with propidium iodide and then analyzed by an Accuri Flow Cytometer. Cell cycle changes were determined by measuring DNA contents as previously described (25)
\